JPMorgan analyst Richard Vosser downgraded GSK to Underweight from Neutral with a price target of 1,350 GBp, down from 1,600 GBp. The analyst continues to see a "bifurcation" in European pharma company outlooks in 2023, both in terms of pipeline readouts and longer-term where "genericisations again need to be navigated." As such, he would avoid companies like GSK and Roche, seeing downside to 2023 consensus estimates and "potentially challenged" 2025-2030 outlooks. Vosser continues to favor companies "which have sustainably higher growth" and "far more" pipeline data points, new launches to drive estimate upgrades.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GSK:
- Barclays views GSK acquisition interest as positive for oncology stocks
- GSK seeks under-appreciated biotechs ‘hiding in plain sight’, FT reports
- Pfizer, Moderna among vaccine makers to watch in 2023, Barron’s says
- ProQR Therapeutics price target raised to $5 from $2 at Raymond James
- Sanofi, Pfizer settled first California Zantac bellwether case, says Barclays